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Aim. To investigate association of the miR-137 expression in neuroblastoma patients with clinical and bio-
logical characteristics of the tumor, and the relationship with survival rates. Methods. qRT-PCR, FISH.
Results. Analysis of 61 primary diagnosed neuroblastoma samples revealed a significantly lower expression 
of miR-137 in patients with the higher risk prognostic factors including the MYCN amplification, onset age, 
disease stage and overexpression of he p53 antagonist MDM2. Although miR-137 is not an independent risk 
factor, its higher expression was significantly associated with both improved event-free survival (5 year: 
50.4 % vs. 12.2 %) and overall survival (5 year: 46.9 % vs. 19.1 %), indicating a potential tumor suppressor 
role in neuroblastoma. Conclusion. We identified miR-137 as a new microRNA of potential importance for 
the neuroblastoma tumor biology. We demonstrated that miR-137 expression can be used as a biomarker to 
stratify the neuroblastoma patients according to the clinical course.
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Introduction
Neuroblastoma (NB) is the most common pediatric 
solid tumor and represents 15 % of all childhood 
cancer deaths [1]. It is a neuroendocrine tumor, aris-
ing from any neural crest element of the sympathetic 
nervous system [2].  Remarkable heterogeneity is 
observed in the tumor phenotype, ranging from 
spontaneous regression to relentless progression. 
NBs are heterogeneous in terms of both genotype 
and clinical behavior. Recent studies have suggested 
that these two features are related, and that the geno-
type frequently is predictive of the response to treat-
ment or the patient outcome [3]. 
NB remains a significant challenge as high-risk 
patients are treated with intensive multimodal the-
rapies but cure rates are still suboptimal. The doz-
ens of clinical and biologic markers have been pro-
posed as being predictive of disease outcome, but 
many clinical correlative studies are focused on the 
identification of the markers, which can be used in 
clinics to optimize  the therapy for an individual 
patient [4].
The aberrant expression of microRNAs has re-
cently been reported in many tumors, including NB. 
MicroRNAs are small non-coding RNAs derived 
from the longer precursors that regulate 30 % of the 
human gene expression at the posttranscriptional 
level by targeting messenger RNAs (mRNAs) [1]. In 
cancer, the function of microRNAs is dependent on 
their mRNA targets, so they can act as tumor sup-
pressors or as oncogenes [5]. 
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MicroRNAs regulate multiple steps of neurogen-
esis. Neurogenesis includes self-renewal and fate 
specification of neural stem cells, migration and 
maturation of young neurons, and functional inte-
gration of new neurons into the neural circuitry. 
MicroRNAs have been shown to regulate all these 
steps of neurogenesis by base-pairing with target 
mRNAs to control the target gene expression [6]. 
The brain-enriched microRNA, miR-137, plays a 
significant role in regulating neuronal maturation. 
Overexpression of miR-137 inhibits the dendritic 
morphogenesis, phenotypic maturation, and spine 
development in both brain and cultured primary neu-
rons. On the other hand, a reduction in miR-137 has 
the opposite effects [7]. MiR-137 may directly or 
indirectly regulate the expression of other “undiffer-
entiated state” genes in the context of preservation of 
the proper central nervous system (CNS) develop-
ment. However, a precise role of this microRNA at 
the early stages of neuronal differentiation during 
the embryonic development   has not been clearly 
identified. 
MiR-137 is located on chromosome 1p22 and is 
downregulated in several human cancer types, in-
cluding the colorectal, bladder, pancreatic, lung can-
cer, glioblastoma, oral cancer and head and neck 
squamous cell carcinoma, and many others [8]. 
Furthermore, the miR-137 overexpression in NB 
cell lines reduces the cell viability and proliferation 
while promoting the neuronal differentiation. Also, 
miR-137 functions as a tumor suppressor in NB by 
downregulating histone demethylase, KDM1A, 
which represses the p53/TP53-mediated transcrip-
tional activation [9]. In recent studies, an inducing 
effect of miR-137 on p53 was shown in different 
cancer and normal cell lines [9–12]. MiR-137 targets 
KDM1A mRNA for degradation and leads to a con-
sequent release of p53 from the KDM1A suppres-
sion which causes the p53 mediated cellular senes-
cence [12].
The p53/MDM2 pathway is often inactivated in 
NB by different mechanisms and is involved in the 
MYCN oncogene overexpression, which plays a 
critical role in determining the clinical behavior of 
NB [13]. MDM2 has been recently characterized in 
NB cell lines as a transcriptional target of MYCN 
[14]. MYCN also transcriptionally upregulates the 
p53 expression in NB and may be an important 
mechanism by which MYCN induces apoptosis 
[15]. However, no evidence of a direct interaction 
with MDM2 or MYCN has been reported for 
miR-137. A number of studies demonstrate the 
changes in the miR-137 functional activity and ex-
pression in NB cells with the MYCN amplification 
(MNA) [9,16,17].
In this study we investigated an association of the 
miR-137 expression in the NB patients with clinical 
and biological characteristics of the tumor and the 
relationship with survival rates.
Materials and Methods
Study subject
61 patients with verified diagnose of NB were en-
rolled into this study. The age of patients ranged 
from 1 month to 17 years, mean age was 
36.4±5.6 months. Stages distribution: I–II stage – 
20 %, III stage – 24 %, IV stage – 56 % of patients. 
All patients were treated in accordance with interna-
tional standards of treatment for NB. Written in-
formed consent was obtained from patients’ parents 
for tissue sampling according to the requirements of 
the protocol N 35 from 1.03.2015 approved by 
Ethical Commission of the National Cancer Institute.
Tumor samples were collected before any cytore-
ductive treatment by biopsy or tumor resection. 
86.9 % of samples were obtained from primary NB 
tumors, 13.1 % – from recurrent and metastatic foci. 
Fresh tumor samples for qPCR analysis were stored 
in “RNA-later” (Ambion, USA) to stabilize RNA 
and DNA; for fluorescent in situ hybridization 
(FISH), formalin-fixed, paraffin embedded tissue 
(FFPE) samples were used.
qRT-PCR
Nucleic acids were extracted from the tumor sam-
ples using Nucleo Spin MiRNA (Macherey-Nagel, 
Germany). Total RNA was reverse transcribed to 
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cDNA with stem-loop primers and the TaqMan 
MicroRNA Reverse Transcription kit (Applied 
Biosystems, USA). To quantify endogenous 
miR-137, TaqMan MicroRNA Assays (Applied 
Bio systems, USA) were used. Level of miR-137 
was normalized to U6 snRNA expression. Real-
time RT-qPCR was performed with 7500 Real-
Time PCR System (Applied Biosystems, USA) 
and TaqMan Universal PCR MasterMix. 
Calculations were performed using the ΔΔCt rela-
tive quantification method. 
Genomic MYCN status was assessed in NB fresh 
tumors by real-time qPCR analysis and FISH for 
FFPE samples. MDM2 mRNA expression level was 
detected by real-time RT-qPCR using TaqMan prim-
ers and probes. MYCN status and MDM2 expression 
in NB tumor samples were analyzed, as previously 
described [18]. Results were normalized to relevant 
controls.
Statistical analysis
All experiments were repeated independently at 
least three times. Gaussian distribution of the group 
was checked with Kolmogorov-Smirnov tests. 
Analysis of the association between the studied 
markers and clinical characteristics of patients was 
performed using U-Mann-Whitney test. Prognostic 
significance of markers was verified with the ROC-
curve (Receiver Operating Characteristic curve). 
Event-free and overall survival was evaluated by 
Kaplan-Meier estimator, statistical significance of 
parameters differences was determined using F-Cox 
criterion. The time to event was calculated as the 
time from study enrollment to the first occurrence of 
relapse, progressive disease, secondary malignancy 
or death. Patients without events were censored at 
the time of last contact. Overall survival time was 
calculated as the time from study enrollment until 
the time of death or the time of last contact if the 
patient was alive. The data were processed with the 
software package Statistica 6.1 using parametric and 
nonparametric methods of statistical analysis and 
MedCalc 12.1.4.0. The difference was considered 
statistically significant at p<0.05.
Results and Discussion
In this study we established that the value of 
miR-137 expression varied quite widely in the NB 
tumor samples depending on the occurrence age, 
di sease stage, MYCN gene status and MDM2 ex-
pression level, and a lower expression was ob-
served in the patients with known higher-risk 
prognostic factors. There was a statistically insig-
nificant decrease in the miR-137 expression level 
in the samples from recurrent and metastatic foci 
comparing to the primary tumors (Fig. 1A). This 
may indicate a role of miR-137 in the development 
and pathogenesis of NB.
We used a Mann-Whitney U-test to identify the 
microRNA differentially expressed between the 
tumors with different molecular and clinical fea-
tures. It is known that the age of patients at the 
time of the disease detection is an independent 
prognostic marker of NB prognosis used by differ-
ent stratification systems [19]. The patients were 
subdivided by age into patients younger than 
12 months, from 12 to 24, 24 months and older. 
Interestingly, miR-137 was differentially ex-
pressed between all these age groups. We observed 
the lowest expression of miR-137 in the patients 
from 12 to 24 months in the primary tumor sam-
ples, p<0.02 (Fig. 1B). This phenomenon still 
needs further study and explanation.
The stage were defined  for the entire NB cohort 
with regard to the metastatic progression (I-II 
without metastases, III with regional metastases 
and IV with distant metastases). We also distinct 
the groups with different MYCN status causing a 
clinically aggressive NB course. The miR-137 ex-
pression was lower in the tumor samples obtained 
from the patients with the disseminated disease 
stages compared with the early-stages, p=0.04 
(Fig. 1C) and in the patients with a high MDM2 
expression compared with a low one, p=0.04 
(Fig. 1E). This testifies to the assumption that this 
microRNA regulates the p53-mediated signaling 
pathway by interaction with MDM2. MicroRNA 
miR-137 was considerably differentially expressed 
between MNA and MYCN-negative tumors, 
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p<0.001 (Fig. 1D). Our findings confirm MNA as a 
major cause of differential microRNA expression 
in NB. The frequency of MNA detected in our 
study (32.7 %) did not differ from the data ob-
tained by other research groups [20].
We used ROC-analysis to assess the prognostic 
significance of the miR-137 expression in the NB 
progression and outcome. Overall (OS) and event-
free survival (EFS) rates were applied as the criteria 
of clinical efficacy for patient distribution on groups 
according to the miR-137 expression level. As fol-
lows, a low miR-137 expression was shown as a 
marker of unfavorable NB and risk of the disease 
recurrence. This marker has sufficient sensitivity and 
specificity for both OS (AUC: 0.67, p=0.03, 
Se: 76.9 %, Sp: 62.5 %, optimal criterion: ≤0.06 a.u.) 
and EFS (AUC: 0.7, p=0.009, Se: 66.7 %, Sp: 72.7 %, 
optimal criterion: ≤0.04 a.u.) and may serve as an 
independent marker of prognosis and stratification 
of the NB patients on risk groups.
The patients were divided into two groups accord-
ing to the miR-137 expression level (high and low 
expression) by the ROC-analysis optimal criterion. 
As the result, the low miR-137 expression was found 
in 52.8 % (28/53) of patients.
Thus, the low miR-137 expression was associated 
with the unfavorable clinical NB features (MNA, 
disease stage, MDM2 expression), indicating a link 
A B
Fig. 1. MiR-137 expression levels 
in NB tumor samples. A – miR-
137 expression in primary tumors, 
recurrent and metastatic foci; B – 
miR-137 expression level in pri-
mary tumors from NB patients, 
depending on the occurrence age; 
C – miR-137 expression in prima-
ry tumors of patients with differ-
ent stages of NB; D – miR-137 
expression level in primary tumors 
with and without MNA; E – miR-
137 expression in primary tumors 
of patients depending on the level 
of MDM2 expression. Box plots 
show miR-137 expression level, 
a.u., the square represents the me-
dian, the box represents the inter-
quartile range, the whiskers repre-
sent 5–95 percentile. 
Notes: p-Values from Mann-Whit-
ney U-tests of <0.05 (*), <0.001 
(**); m. – months; a.u. – arbitrary 
units.
C D
E
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between the miR-137 under expression and the high-
risk phenotype.
To confirm the obtained results we have ana-
lyzed the overall (OS) and event-free survival 
(EFS) of the NB patients depending on the miR-
137 expression level. The analysis of the miR-137 
expression level in the primary diagnostic neuro-
blastoma samples revealed a significant associa-
tion of a low miR-137 expression with poor EFS 
and OS. We found that the patients with a low 
miR-137 expression had less favorable EFS 
(p<0.01) and OS (p<0.01) than the patients with 
the highly miR-137 expressed tumors (12.2 % and 
19.1 % vs 50.4 % and 46.9 %, respectively; Fig. 2). 
Such a significant difference suggests that this 
marker can play a substantial role in the pathogen-
esis and progression of NB.
Therefore, a decreased miR-137 expression was 
associated with a risk of the disease recurrence and 
generally with the reduction of patients’ lifetime. 
Such a significant difference suggests that this mark-
er plays a substantial role in the pathogenesis and 
progression of NB.
Taking into account a strong correlation with 
major determinants of tumor biology and clinical 
course, we consider miR-137 as a miRNA of po-
tentially high importance in the NB tumor biology. 
Our results are in line with the recent report by 
Althoff K. et al. [9], who also reported a high miR-
137 expression to be correlated with a favorable 
prognosis for the NB patients. To date, little is 
known about the miR-137 functionality or involve-
ment in the disease. The role of miR-137 in gen-
eral as well as in the  NB tumor biology strongly 
warrants further investigations. We assume that 
miR-137 may be an indirect upstream regulator of 
p53 mostly by the degradation of KDM1A and the 
violation of its expression in NB is one of the pos-
sible mechanisms of the p53 pathway deregulation 
along with other alterations. The pathways, by 
which p53 regulates this microRNA, as well as 
possible interplay with MYCN and MDM2 remain 
to be elucidated.
Conclusions
Taken together, we here demonstrate that the mi-
croRNA expression can be used as a biomarker to 
stratify the NB patients according to the clinical 
course. We identified that miR-137 is potentially im-
portant for the NB tumor biology. The expression of 
miR-137, which is repressed in the MYCN-amplified 
tumors, was negatively associated with the MDM2 
gene expression and predictive of survival. Further 
studies are necessary to test a predictive facility of 
the miRNA-137 expression in a larger number of pa-
tients.
Fig. 2. Kaplan-Meier graphs of OS (A) and EFS (B) for NB patients regarding miR-137 expression level.
A B
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Експресія мікроРНК-137 при нейробластомі: роль 
в клінічному перебігу захворювання.
М. В. Іномістова, Н. М. Храновська, О. В. Скачкова, 
Г. І. Климнюк, С. В. Демидов, Н. М. Свергун 
Мета. Дослідити асоціацію експресії мікроРНК-137 у хворих 
на нейробластому з клінічними та біологічними характеристи-
ками пухлини та зв’язок з виживаністю. Методи. qRT-PCR, 
FISH. Результати. Аналіз рівнів експресії мікроРНК-137 в 
61 зразках первинно діагностованої нейробластоми показав, 
що у хворих з відомими прогностичними факторами високого 
ризику, такими як ампліфікація онкогена MYCN, вік на момент 
виявлення захворювання, IV стадія захворювання і висока екс-
пресія MDM2, антагоніста p53 з онкогенними властивостями, 
рівень експресії мікроРНК-137 значно знижений. Незважаючи 
на те, що експресія мікроРНК-137 не є незалежним фактором 
ризику, її підвищення в значній мірі пов’язане як з покращен-
ням безрецидивної виживаності (5-ти річна: 50,4 % проти 
12,2 %), так і загальної виживаності (5-ти річна: 46,9 % проти 
19,1 %), що вказує на її потенційну роль як онкосупрессора при 
нейробластомі. Висновки. Ми визначили, що мікроРНК-137 
має потенційно важливу роль в розумінні біології нейробласто-
ми. Нами показано, що експресія мікроРНК-137 може бути ви-
користана в якості біомаркера для стратифікації пацієнтів за 
групами ризику та клінічним перебігом нейробластоми.
К л юч ов і  с л ов а: нейробластома, експресія мікроРНК-137
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Экспрессия микроРНК-137 при нейробластоме: роль 
в клиническом течении и исходе заболевания.
М. В. Иномистова, Н. Н. Храновськая, О. В. Скачкова, 
Г. И. Климнюк, С. В. Демидов, Н. Н. Свергун
Цель. Исследовать ассоциацию экспрессии микроРНК-137 у 
больных с нейробластомой с клиническими и биологическими 
характеристиками опухоли и ее связь с выживаемостью. 
Методы. qRT-PCR, FISH. Результаты. Анализ уровней экс-
прессии микроРНК-137 в 61 образцах первично диагностиро-
ванной нейробластомы показал, что у больных с известными 
прогностическими факторами высокого риска, таких как ам-
плификация онкогена MYCN, возраст на момент выявления 
заболевания, IV стадия заболевания и высокая экспрессия 
MDM2, антагониста p53 с онкогенными свойствами, уровень 
экспрессии микроРНК-137 значительно снижен. Несмотря на 
то, что экспрессия микроРНК-137 не является независимым 
фактором риска, ее повышение в значительной степени связа-
но как с улучшением безрецидивной выживаемости (5-летняя: 
50,4 % против 12,2 %), так и с общей выживаемостью (5-лет-
няя: 46,9 % против 19,1 %), что указывает на ее потенциальную 
роль как онкосупрессора при нейробластоме. Выводы. Мы 
определили, что микроРНК-137 имеет потенциально важную 
роль в понимании биологии нейробластомы. Нами показано, 
что экспрессия микроРНК-137 может быть использована в ка-
честве биомаркера для стратификации пациентов по группам 
риска и клиническим течением нейробластомы. 
К л юч е в ы е  с л ов а: нейробластома, экспрессия мик-
роРНК-137
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